Keywords: exelixis, b-ms, complete, set, cancer, targets, bristol-myers

Exelixis and B-MS complete set of cancer targets

Article | 12 August 2002

Exelixis and Bristol-Myers Squibb have completed selection of a set ofhighly-validated cancer targets, which also triggers a significant milestone payment ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bristol-Myers Squibb

Drug Discovery

Go to company listing